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Abstract
The hyaluronic acid receptor for endocytosis (HARE)/Sta-
bilin-2 is the primary systemic scavenger receptor for 13 li-
gands including hyaluronan (HA), heparin and chondroi-
tin sulfates. Most ligand-binding sites are within the 190 kDa 
isoform, which contains ~25 kDa of N-glycans and is the C-
terminal half of the full-length 315 kDa HARE. Glycopro-
teomic analyses of purified recombinant human 190-HARE 
ecto-domain identified a diverse population of glycans at 10 
of 17 consensus sites. The most diversity (and the only si-
alylated structures) occurred at N2280, within the HA-binding 
Link domain. To determine if these N-glycans are required 
for HA binding, we created human Flp-In 293 cell lines ex-
pressing membrane-bound or soluble ecto-domain variants of 
190-HARE(N2280A). Membrane-bound HARE lacking Link 
domain N-glycans mediated rapid HA endocytosis, but puri-
fied 190-HARE(N2280A) ecto-domain showed little or no HA 
binding in ELISA-like, HA-HARE pull-down assays or by sur-
face plasmon resonance analysis (which detected very high 
apparent affinity for 190-HARE ecto-domain binding to HA; 
Kd = 5.2 nM). The results indicate that Link domain N-glycans 
stabilize interactions that facilitate HA binding to HARE. 
Keywords: coated pit mediated, conformation, glycosamino-
glycan turnover, HA binding affinity, Stabilin-2
Introduction
The hyaluronic acid (HA) receptor for endocytosis (HARE), 
also known as Stabilin-2 or FEEL-2, is a clearance/scavenger 
receptor that is highly expressed in the sinusoidal endothelial 
cells of liver, lymph node and spleen (Weigel and Yik 2002). 
HARE is also found in oviduct, corneal and lens epithelium, 
heart valve mesenchymal cells, ependymal cells lining ven-
tricles in brain, macrophages and epithelial cells covering re-
nal papillae (Falkowski et al. 2003). Human HARE is a 2551 
aa, 315 kDa, type-1 transmembrane receptor expressed on 
the cell surface and in intracellular (e.g. endocytic) compart-
ments. The receptor is composed of modular repeats of epi-
dermal growth factor (EGF), EGF-like and Fasciclin domains. 
Native tissues express two HARE isoforms of different mass 
(190 kDa and 315 kDa) that are not splice variants (Zhou et 
al. 1999, 2003; Weigel et al. 2002). In cells stably expressing 
cDNA encoding full-length 315-HARE, a small fraction of the 
315 kDa protein is proteolytically cleaved to create the 190-
HARE, the C-terminal 1416 aa of the 315-HARE protein (Har-
ris et al. 2007). Both HARE isoforms are functional endocytic 
receptors, targeted to coated pits, with identical ligand-bind-
ing profiles (Harris et al. 2004, 2007; Harris and Weigel 2008). 
A defining feature of HARE is its Link domain, 168 aa from 
the membrane domain, which has a sequence similar to Link 
domains in other HA-binding proteins such as TSG-6, CD44 
and aggrecan (Day and Prestwich 2002). 
HARE recognizes at least 13 distinct ligands, including 
HA (Yannariello-Brown et al. 1997; Politz et al. 2002), colla-
gen N-terminal propeptides (Hansen et al. 2005), advanced 
glycation end-products (Tamura et al. 2003), acetylated low 
density lipoprotein (Adachi and Tsujimoto 2002), chondroi-
tin and chondroitin sulfates type A–E (Harris et al. 2004), 
αMβ2 integrin (Jung et al. 2007), heparin (Harris et al. 2008) 
and phosphatidylserine (Park et al. 2008a). The function of 
HARE/Stab2 in liver and lymph nodes to remove circulating 
HA and chondroitin sulfates has been known for over two 
decades. However, three recent findings indicate that HARE 
mediates additional important functions: i) HARE mediates 
intracellular ERK signaling in response to HA binding (Kyo-
sseva et al. 2008); ii) HARE is the long-sought macrophage 
apoptotic receptor that recognizes exposed phosphatidylser-
ine on dying cells and mediates their phagocytosis (Park et 
al. 2008a, 2008b); and iii) HARE is the major liver clearance 
receptor for circulating heparin (Harris et al. 2008, 2009). 
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The large size of HARE and its recognition of multiple li-
gands present challenges in efforts to define subdomains 
within the protein that mediate specific ligand-binding 
events. Considerable additional complexity is contributed by 
earlier findings that the 190-HARE and 315-HARE glycopro-
teins contain >25 kDa in N-glycans (Weigel and Weigel 2003; 
Zhou et al. 2003). Within the 190-HARE, 13 consensus N-gly-
cosylation sites are conserved among rat, mouse and human 
(including one NCTC site). In order to express and charac-
terize stable HARE subdomains that retain a specific ligand-
binding activity, it is important to know more about HARE 
N-glycans, the sites that are modified and if N-glycans at 
particular sites are important for ligand binding. 
Our goals in this study were to identify the types of N-
glycans at occupied Asn sites in 190-HARE and to deter-
mine if glycans at N2280 in the Link domain are required for 
HA binding by purified ecto-domain or membrane-bound 
receptor. 
Results
Glycomics analysis of s190-HARE
Recombinant soluble 190-HARE ecto-domain protein (s190-
HARE), containing C-terminal His-6 and V5 tags, was ex-
pressed in human Flp-In 293 cells, purified from media and 
analyzed by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE). The s190-HARE band was ex-
cised, digested with trypsin and then with PNGase-F. The 
released N-glycans were separated from peptides by Sep-
Pak C18 purification, permethylated and analyzed by ma-
trix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) (Figure 1). For each ion, pu-
tative structural assignments were made based on composi-
tional information and knowledge of mammalian glycosyl-
ation biosynthetic pathways. Where possible, components 
observed in the MALDI-MS profile (Figure 1) were subjected 
to electrospray ionization tandem mass spectrometry (ESI-
MS/MS) to assist sequence assignment (not shown). 
The mass spectrum indicates that s190-HARE N-glycans 
have compositions consistent with minor amounts of high 
mannose structures (Hex5–7HexNAc2) plus major complex 
type bi-, tri- and tetra-antennary glycans of compositions 
NeuAc0–2Fuc0–2Hex3–7HexNAc4–7. The most abundant ion 
(m/z 2285) has a composition (Fuc1Hex4HexNAc5) consis-
tent with either a core fucosylated bisected bi-antennary gly-
can or a core fucosylated tri-antennary glycan, each having 
a single antenna terminated with galactose (Figure 1). The 
next two most abundant components (m/z 2244 and 2489; 
Figure 1), 70% and 50% of the base (highest) peak, respec-
tively, have two antennae capped with galactose. Many com-
Figure 1. Glycomic analysis of s190-HARE. MALDI-TOF mass spectrum of permethylated s190-HARE N-glycans. N-Glycans were derived from 
the 50% (v/v) acetonitrile fraction from a C18 Sep-Pak. All molecular ions are [M+-Na]+-, and nominal masses of the 12C isotope are shown. The 
putative structures shown are based on composition, tandem mass spectrometry analysis and knowledge of biosynthetic pathways. Symbol code: 
Gal (yellow circle), Man (green circle), GlcNAc (blue square), Fuc (red triangle) and NeuAc (purple diamond) 
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ponents are of more modest abundance. Those showing sig-
nals greater than 5% of the base peak include glycans lacking 
fucose (for example m/z 2070 and 2111; Figure 1), and con-
stituents whose compositions are consistent with the pres-
ence of a fucosylated antenna in addition to core fucose (m/z 
2418 and 2459; Figure 1). Very few glycans are sialylated, 
and based on comparisons of peak heights, they constitute 
less than 5% of the total population. Most sialylated glycans 
have only a single sialic acid (m/z 2605, 3055 and 3504; Fig-
ure 1), although a trace amount of a disialyl component was 
identified at m/z 3865. 
Glycoproteomic analysis of s190-HARE
We performed extensive glycoproteomic analyses on gel-pu-
rified s190-HARE protein using a variety of proteases, alone 
and in combinations, as well as chemical cleavage. Result-
ing peptides were analyzed by nano-liquid chromatography 
(LC)-ESI-MS/MS. As glycosidic bond fragmentation occurs 
during collisional activation in ESI-MS/MS and results in di-
agnostic fragment ions at m/z 204 (HexNAc) and 366 (Hex-
HexNAc), MS/MS spectra were analyzed for these ions, and 
when present the spectra were examined manually to iden-
tify the glycopeptide. Using this technique, we identified 
the populations of N-glycans at 10 of the 17 consensus sites 
for N-glycosylation (Figure 2). Of the 10 sites, two are local-
ized to regions of special biological interest. The first impor-
tant site is at N2280KS within the HA-binding Link region. 
Although the HARE Link domain has not been indepen-
dently expressed and assessed directly for HA-binding activ-
ity, cells expressing a 190-HARE(ΔLink) mutant endocytose 
<10% of the HA endocytosed by wild type (WT) 190-HARE 
cells (Kyosseva et al. 2008; Harris and Weigel 2008). The 
N2280 site is occupied by a very heterogeneous range of N-
glycans with and without sialic acid. In fact, all the sialylated 
structures identified were found only at N2280. N-Glycans 
with compositions consistent with bisected structures are 
also a feature of the glycan population at N2280 (Figure 2). A 
second site of presumed importance is N2296, which is in the 
stem region between the Link and membrane domains. This 
site carries the most homogeneous range of N-glycans of all 
the identified sites, having a limited number of small neu-
tral glycans with compositions Fuc0–1Hex4–5HexNAc4–5 (Fig-
ure 2). The N2296CT site is also unusual in that it overlaps a 
CTC sequence, both of which are conserved. In such cases, 
disulfide bond formation might preclude glycosylation and 
vice versa. 
Figure 2. N-Glycosylation sites and N-glycans identified in s190-HARE. The glycans observed at the indicated sites are shown; numbering is based 
on the full-length 2551 aa HARE. The glycan structures are based on the composition of the glycan, as calculated from the mass of the glycopep-
tide minus the mass of the peptide, complemented by information from CAD-ESI-MS/MS data and from the glycomic profile shown in Figure 1. 
Symbol code: Gal (yellow circle), Man (green circle), GlcNAc (blue square), Fuc (red triangle) and NeuAc (purple diamond) 
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In addition to N-glycopeptides observed during the 
LC-ESI-MS/MS analysis of s190-HARE, ions consistent 
with two O-glycopeptide glycoforms were also detected. 
The data were attributable to the peptide CLPAYTGDG-
KVCTL1555 carrying O-glycans with compositions HexNAc 
and HexHexNAc. Peptide fragmentation enabled sequenc-
ing through most of the peptide and assignment of T1547 as 
the substituted residue (not shown). We do not know what 
other sites may also be O-glycosylated, but results shown be-
low confirm that s190-HARE contains only a few O-glycans. 
Estimation of HARE N-glycan content
Based on treatment of nonreduced protein with PNGase-F, we 
concluded that the two isoforms of purified native rat and hu-
man HARE contain ~25 kDa of N-glycans (Zhou et al. 2000, 
2003; Weigel and Weigel 2003), equivalent to ~10 oligosaccha-
rides. To complement the present glycomics analysis, we de-
termined if similar results were obtained for recombinant WT 
190-HARE and 315-HARE during biosynthesis. Metabolic 
pulse-chase labeling of human Flp-In 293 cells expressing 190-
HARE or 315-HARE with 35S-Met/Cys revealed increased 
sizes of 190-HARE and 315-HARE between 60 and 120 min 
(Figure 3A), as expected for the addition and assembly of N-
glycans in the ER/Golgi. After 2 h, most labeled protein was 
~25 kDa larger than the initial core protein. 
PNGase-F treatment of purified and reduced s190-
HARE also released ~25 kDa of N-glycans (Figure 3B), in-
dicating that the majority of N-glycans are in the C-termi-
nal 190-HARE portion of 315-HARE. We also determined if 
some N-glycans were not released from the folded protein 
by comparing protein mass shifts after digestion of reduced 
or nonreduced HARE. Reduced and alkylated s190-HARE 
shifted from ~150 kDa (Figure 3B, lane 1) to ~170 kDa (Fig-
ure 3B, lane 3), and the mass loss of ~25 kDa after PNGase-
F treatment was similar for reduced and nonreduced recep-
tor (Figure 3B, lanes 2 and 4). The mass of Endo-H-treated 
s190-HARE was identical to that of undigested protein (Fig-
ure 3C, lanes 2 and 4), indicating that essentially all WT s190-
HARE N-linked glycans are mature complex structures with 
few high mannose or immature N-glycans (consistent with 
the glycomics analysis; Figure 1). To assess the amount of 
O-glycans or PNGase-F-resistant N-glycans present, we 
also treated the protein with trifluoromethanesulfonic acid 
(TFMS) to release all glycans (Edge et al. 1981). TFMS-treated 
and PNGase-F-treated s190-HARE proteins differed by only 
4 kDa (Figure 3C, lanes 1 and 3), indicating that s190-HARE 
has little O-glycosylation. 
Cell lines expressing 190-HARE(N2280A)
To determine if Link domain N-glycans are required for 
function, we made cDNA variants of ecto-domain or mem-
brane-bound 190-HARE with a single N(2280)A mutation to 
eliminate N-glycosylation at N2280KS. We characterized mul-
tiple stably transfected Flp-In 293 cell lines expressing ei-
Figure 3. Estimation of s190-HARE N-glycan content. A. Glycosylation 
of HARE during biosynthesis. Cells expressing either membrane-
bound 190-HARE (top) or 315-HARE (bottom) were incubated with 
35S-Met/Cys for 5 min, washed and then incubated (chased) for the in-
dicated times with fresh DMEM as described in Materials and meth-
ods. HARE proteins were purified using mAb-30, separated by SDS–
PAGE, and the gels were processed for autoradiography. The nascent 
HARE core proteins (solid arrows) are shifted to larger mass (open ar-
rows) as they are glycosylated and move from the ER/Golgi to the cell 
surface. B. Effect of reduction on N-glycan release from s190-HARE. 
Purified s190-HARE was untreated (lanes 1 and 2) or reduced and 
alkylated (lanes 3 and 4) and then incubated with (lanes 2 and 4) or 
without (lanes 1 and 3) PNGase-F. Samples were separated by SDS–
PAGE, electro-blotted to nitrocellulose, and HARE was detected using 
anti-V5 Ab. C. Effect of chemical or enzymatic deglycoslyation. Puri-
fied s190-HARE was reduced and alkylated and then either untreated 
(lane 2) or treated with TMFS (lane 1), PNGase-F (lane 3) or Endo-H 
(lane 4) and analyzed as above. 
Figure 4. 190-HARE(N2280A) cells coexpress a smaller variant with 
altered glycosylation that is delivered to the surface. A. Although 
HARE expression levels varied among the indicated stable cell lines, 
each expressed two membrane-bound 190-HARE(N2280A) bands 
that bind 125I-HA in ligand blot (LB) assays. After exposure on film, 
western blot (WB) analysis with anti-V5 Ab visualized the HARE 
doublet. B. Both 190-HARE(N2280A) variants are on the cell sur-
face. 190-HARE(N2280A) cells were incubated for 1 h at 4°C with 
HBSS containing 1 μg/mL mAb-30 with 0.055% digitonin (Weigel et 
al. 1983) [permeabilized to assess Total] or without [nonpermeabi-
lized to assess Surface only]. Solubilized Ab-HARE complexes were 
captured using Protein A/G Sepharose. After centrifugation, the 
resin was eluted with 2× Laemmli buffer (Laemmli 1970), and the el-
uate was separated by SDS–PAGE, electro-blotted and HARE pro-
teins detected by enhanced chemiluminescence using anti-V5 Ab. The 
ratios of the two HARE bands recovered in each lane were the same 
as assessed in digital images, and the Total signal was attenuated by 
~80% for comparison to the Surface signal (Harris et al. 2004, 2007). 
C. The smaller band has immature glycans. Immuno-purified nonre-
duced s190-HARE(N2280A) protein was subjected to SDS–PAGE after 
no treatment (lane 1) or digestion with PNGase-F (lane 2) or Endo-H 
(lane 3). The arrow indicates the minor smaller band, which was com-
pletely shifted by Endo-H, which did not affect the larger band.
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ther 190-HARE variant. In all clones examined (Figure 4A, 
top), membrane 190-HARE(N2280A) was a doublet (sep-
arated by ~10 kDa), unlike WT 190-HARE (Figure 4A, last 
lane); the major upper band migrated at the WT position. 
Both HARE bands bound 125I-HA in a ligand blot assay (Fig-
ure 4A, bottom). 
Since the smaller 190-HARE(N2280A) binds HA, it might 
also mediate HA endocytosis. Although this could not be 
tested directly (due to endocytosis mediated by the normal 
variant), we determined if the smaller variant is delivered 
to the cell surface. Cultured cells were incubated at 4°C with 
HARE-specific mAb-30 (Zhou et al. 2000), with or without 
digitonin, to monitor HARE recovery from intact or permea-
bilized cells (Weigel et al. 1983), respectively. HARE-antibody 
(Ab) complexes were then solubilized, captured using Pro-
tein A/G Sepharose and analyzed by SDS–PAGE and west-
ern blotting (Figure 4B). Since the intracellular receptor pool 
is 5–6-fold greater than the surface pool (Harris et al. 2004, 
2007), the Total HARE signals (Figure 4B) were adjusted by 
this factor to compare the two doublet bands. The fraction of 
the smaller HARE band recovered by mAb bound to cell sur-
faces only (no digitionin) was identical to that for mAb bound 
to intracellular and surface HARE (digitonin-permeabilized). 
Thus, the smaller 190-HARE(N2280A) species is not a biosyn-
thetic intermediate; it is a folded glycoform (different than 
WT) that traffics normally to the cell surface. 
To test if the lack of N-glycans at N2280 alters the normal 
processing of 190-HARE(N2280A) proteins during biosynthe-
sis (e.g. proteolysis or smaller N-glycans), we assessed the size 
of the two s190-HARE(N2280A) proteins after treating pu-
rified receptor with PNGase-F or Endo-H to release, respec-
tively, almost all or only immature (e.g. high mannose) gly-
cans. Digestion with PNGase-F collapsed the doublet into 
a single band (Figure 4C, lanes 1 and 2), demonstrating that 
proteolysis had not occurred. Endo-H digestion quantitatively 
shifted the mass of the smaller HARE band but, as expected, 
not the larger normal band (Figure 4C, lanes 1, 2 and 3). The 
broad PNGase-F treated band (lane 2) still contains N-glycans, 
whereas the Endo-H product (lane 3) does not, since PNGase-
F digestion of reduced and alkylated doublet yielded one pro-
tein of the same size as the small band in lane 3 (not shown). 
Cells expressing 190-HARE(N2280A) mediate HA 
endocytosis
Previous studies showed that Flp-In 293 cells expressing ei-
ther HARE isoform show robust binding and coated pit-
mediated endocytosis of HA, whereas mock or empty vec-
tor (EV) transfected cells show essentially no specific HA 
binding or endocystosis, and HA uptake is reduced >90% in 
190-HARE(ΔLink) cells compared to WT (Harris et al. 2004, 
2007; Harris and Weigel 2008; Kyosseva et al. 2008; Pandey 
et al. 2008). Cells expressing 190-HARE lacking N2280-gly-
cans also mediated specific binding and endocytosis of 125I-
HA (Figure 5). Five cell lines expressing the N2280 variant 
each internalized HA rapidly and efficiently, with linear ki-
netics similar to WT and at similar rates (±30%), for at least 
7 h (data were normalized for total HARE content relative 
to WT at 100%; Figure 5). During this time, the cell surface 
190-HARE pool would be internalized and recycled back to 
the surface ~46 times (Harris et al. 2004). In contrast, the spe-
cific HA uptake rate by EV and 190-HARE(ΔLink) cells was 
−1.2% and 2.8%, respectively, of WT. The variability in HA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
uptake rates by variant HARE cell lines may reflect unique 
clonal differences in the function of the complex cellular 
pathways for coated pit-mediated endocytosis and recep-
tor recycling (Harris et al. 2004). The results indicate that the 
ability of membrane-bound HARE(N2280A) variant to bind 
and mediate endocytosis of HA is not affected by lack of the 
Link domain N-glycans. 
Purified soluble 190-HARE(N2280A) ecto-domain does not 
bind HA in three in vitro assays
All s190-HARE(N2280A) cell lines tested expressed the ecto-
domain as a single band that bound HA in a ligand blot assay 
(Figure 6A), and no differences were seen in overall glyco-
sylation due to loss of a glycan at N2280 (not shown); the gly-
can mass at N2280 is <4 kDa. Membrane 190-HARE(N2280A) 
and WT 190-HARE bind HA similarly in ligand blot assays 
and internalize HA in a similar fashion (Figures 4A and 5). 
There were also no differences in HA-binding ability of the 
soluble and membrane 190-HARE(N2280A) proteins in li-
gand blot assays (Figure 6A). 
In contrast, three other independent methods to evaluate 
HA-binding activity showed that the s190-HARE(N2280A) 
ecto-domain binds much less or no HA compared to WT 
ecto-domain (Figure 6B–D). The negative control was s190-
HARE(Δlink), which does not bind HA. In a HARE pull-
down assay, using biotin (b)-HA bound to SA-Agarose, 
two independent purified s190-HARE(N2280A) prepa-
rations showed only a trace of HA binding, whereas all 
the WT s190-HARE present, but no s190-HARE(Δlink), 
bound to HA (Figure 6B). Similarly, in an ELISA-like assay, 
Figure 5. Cell lines expressing 190-HARE(N2280A) endocytose 
HA normally. WT 190-HARE, EV, 190-HARE(ΔLink) cells and five 
190-HARE(N2280A) cell lines, indicated by different numbers, were 
incubated for up to 7 h at 37°C with 125I-HA (plus or minus excess un-
labeled HA) and processed at the indicated times to assess specific HA 
endocytosis as described in Materials and methods. Specific endocy-
tosis values are presented as mean (n = 3) CPM/μg cell lysate protein, 
normalized for HARE expression relative to WT, which was 100%. 
SEM values for nearly all data points were within ± 4% and all SEM 
values were within < ± 6.3%.
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 s190-HARE(N2280A) binding to immobilized HA was only 
18% of the WT value (Figure 6C). Finally, we used sur-
face plasmon resonance (SPR) with b-HA as the ligand, at-
tached to a SA chip, to quantify HA binding to each of the 
three ecto-domains used as the analyte (Figure 6D). No de-
tectable binding to HA was observed for either the s190-
HARE(N2280A) or the s190-HARE(ΔLink) ecto-domains 
(Figure 6D, middle and bottom panels). In contrast, WT 
s190-HARE bound HA in a reversible manner (Figure 6D, 
top panel) with exceptionally high apparent affinity (Kd = 
5.2 nM) calculated from the measured kinetic values for 
kon (1.58 × 105 s−1 mol−1) and koff (8.22 × 10−4 s−1). This af-
finity of HARE binding to HA is the highest of all known 
hyalectins. 
Discussion
We wanted to determine if the HARE Link domain is N-gly-
cosylated and, if so, whether these N-glycans are required 
for HA binding. Two of the present findings indicate an un-
expected complexity and importance for the physiologi-
cal functions of HARE Link module N-glycans. First, of 10 
glycosylated sites within the 190-HARE identified to con-
tain multiple N-glycoforms, N2280 in the Link domain site 
showed the greatest structural diversity and was the only 
site with sialylated glycans. Second, although membrane-
bound 190-HARE(N2280A) binds and endocytoses HA nor-
mally, the ecto-domain shows impaired or no HA binding in 
three of four in vitro assays. 
HARE has the highest apparent affinity for binding to HA 
(Kd = 5–23 nM; Figure 6D and Harris et al. 2004, 2007) of all 
hyalectins, surpassing CD44 [Kd = 5–150 µM (Skelton et al. 
1998)], TSG-6 [Kd = 200–500 nM (Kahmann et al. 2000)], ag-
grecan [Kd = 226 nM (Watanabe et al. 1997)] and Link pro-
tein [Kd = 82 nM (Watanabe et al. 1997)]. These values are 
all apparent (van der Merwe et al. 1993) since the presence 
of dimers and oligomers in the purified proteins is gener-
ally unknown and the HA ligand is inherently multivalent. 
Nonetheless, the Kd value of 5 nM determined here from SPR 
data (Figure 6D) is in excellent agreement with previously 
determined Kd values of 10 nM and 22 nM for HA binding to 
purified s315-HARE and s190-HARE, respectively, in ELISA-
like assays (Harris et al. 2007), and of 7 nM for HA binding 
to membrane-bound 190-HARE in cells (Harris et al. 2004). 
Both HARE isoforms have identical affinities for binding 
to heparin or HA and identical binding profiles for at least 
six other ligands (Harris and Weigel 2008). More than 90% of 
the HA-binding activity of HARE is lost in the HARE(ΔLink) 
variant (Kyosseva et al. 2008). CS-A, CS-C and CS-D also 
bind within the HA-binding Link domain of HARE (Harris 
et al. 2004, 2007; Harris and Weigel 2008). In contrast, s190-
HARE(ΔLink) still binds to acetylated low density lipopro-
tein, heparin, dermatan sulfate (CS-B) and CS-E. Thus, HARE 
specifically binds to HA and heparin at two independent and 
nonoverlapping sites. Not all Link modules that bind both HA 
and heparin show independent binding. For example, unlike 
HARE (Harris and Weigel 2008; Harris et al. 2008), the TSG-6 
Link module binds each ligand in separate grooves, but HA 
binding prevents heparin binding or vice versa; HA and hepa-
rin do not bind simultaneously (Mahoney et al. 2005). 
Figure 6. The 190-HARE(N2280A) ecto-domain does not bind HA in 
most assays. A. Ligand blot assay. Soluble (SOL) s190-HARE(N2280A) 
is a single band by western blot (WB) that is smaller than membrane-
bound (MEM) 190-HARE(N2280A). Both bind 125I-HA in ligand 
blot (LB) assays. B. HARE pull-down assay. SA-agarose with bound 
b-HA was incubated with 1 μg of purified s190-HARE [WT], s190-
HARE(ΔLink) [ΔL] or s190-HARE(N2280A) [N-A; two different prep-
arations] C. ELISA-like assay. Binding of the three purified ecto-do-
mains to HA immobilized on plate wells was quantified by A405 as 
described in “Materials and methods.” D. Surface plasmon resonance 
assay. The three purified ecto-domains at 12.5 nM (lower lines) and 
50 nM (upper lines) were each analyzed for binding to immobilized 
HA and then, after 60–90 s, for dissociation in buffer without ecto-do-
main as described in “Materials and methods.”
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Human 315-HARE has 28 predicted N-glycosylation sites, 
of which 17 are within the 190-HARE. Our glycoproteomic 
results identified multiple types of glycans on 10 of these 17 
sites. Of these 10 human glycosylation sites, nine are con-
served in rat and mouse HARE (Zhou et al. 2002, 2003), indi-
cating their importance to the functions of HARE. PNGase-
F treatment releases ~25 kDa of glycans from either isoform 
and from either rat or human native or recombinant HARE 
(Zhou et al. 1999, 2002, 2003). The same result was obtained 
with membrane-bound or soluble 190-HARE or 315-HARE. 
Glycans identified at the 10 sites (Figure 1) ranged in mass 
from 1580 Da to 3866 Da (7 to 16 sugars) corresponding to a 
total average mass of ~25 kDa. Thus, most of the N-glycans 
attached to the full-length protein may be within its C-termi-
nal 190-HARE region. 
Several groups discovered that N- or O-glycans can in-
fluence the HA-binding function of proteins containing a 
Link module (Bennett et al. 1995; Katoh et al. 1995; Lesley 
et al. 1995; Bartolazzi et al. 1996; Dasgupta et al. 1996; Eng-
lish et al. 1998; Skelton et al. 1998). Although initially con-
troversial, it is now generally accepted that N-glycans on the 
Link module of the HA receptor CD44 influence HA bind-
ing. In most cases, the presence of an N-glycan inhibits HA 
binding. The HA-binding ability of LYVE-1, a lymphatic HA 
receptor, is inhibited by sialylation of O-glycans (Nightin-
gale et al. 2009), and HA binding could be unmasked in si-
alylated native or recombinant LYVE-1 by neuraminidase 
treatment. Locations of the sialylated O-glycans are un-
known, but thought not to be on the LYVE-1 Link module. 
Inhibition due to the presence of a glycan can sometimes be 
attributed to steric occlusion; HA cannot physically interact 
with key binding site residues. Another attractive and in-
herently more responsive mechanism would involve revers-
ible interactions between an oligosaccharide and domains 
within the protein to create an unfavorable conformation for 
HA binding (i.e. a temporary self-occluding steric effect). Re-
versing or disrupting this oligosaccharide interaction to al-
low a conformation favorable for HA binding might occur 
by multiple mechanisms, such as an allosteric-like response 
upon binding another protein or small ligand or by remov-
ing sialic acid residues needed to maintain the unfavorable 
conformation. 
In summary, our results show that lack of an N-glycan 
on the HARE Link domain: (i) compromises HA binding 
to purified ecto-domain in three of four in vitro assays and 
(ii) does not decrease HA binding or endocytosis mediated 
by the membrane-bound protein. These effects indicate that 
N2280 oligosaccharides are important for the soluble trun-
cated ecto-domain to maintain an HA binding conforma-
tion. Despite the ability of 190-HARE(N2280A) cells to in-
ternalize HA normally, preliminary results indicate that this 
variant HARE mediates little or no HA-dependent intracel-
lular ERK activation (M.S. Pandey and P.H. Weigel unpub-
lished). As noted above, the HARE Link glycans may di-
rectly interact (or indirectly facilitate interaction) with an 
adjacent HARE domain near the membrane to create an ac-
tive HA binding site and ERK signaling competence. Sup-
porting the idea that these activities depend on specific con-
formations, we previously found that the ability of mAb-174 
to block HA binding by HARE in rat liver sinusoidal en-
dothelial cells was lost at lower temperature (Weigel et al. 
2003). We concluded that HARE undergoes a conformation 
change between 37°C and 4°C that does not prevent HA 
binding to HARE but that alters the epitope recognized by 
mAb-174 so that it does not block HA binding. Based on the 
present results, this conformational change is likely depen-
dent on the Link domain glycan. 
Materials and methods
Reagents and buffers
Flp-In 293 cells, culture medium, transfection reagents, 
cDNA purification and amplification reagents and plas-
mids were from Invitrogen-Gibco (Carlsbad, CA). pfu ul-
tra HF was from Stratagene (La Jolla, CA). EasyTag Ex-
pre35S35S Labeling Mix (35S-Methionine/Cysteine) was 
from Perkin Elmer (Waltham, MA). Classic Blue BX film 
was from MidSci (St. Louis, MO). Streptavidin (SA), bio-
tin-LC-hydrazide, sulfo-NHS-SS-biotin, SnakeSkin dialysis 
tubing (MWCO 3500) and luminol and peroxide solutions 
were from Pierce (Rockford, IL). RNA purification kits were 
from Qiagen, and plasmid DNA purification and cloning 
kits were from Fermentas (Glen Burnie, MD). Polysorp well 
strips were from Nunc (Roskilde, Denmark), and p-nitro-
phenylphosphate was from Kirkegaard & Perry Laborato-
ries, Inc. (Gaithersburg, MD). HA from Genzyme (Framing-
ham, MA) was acid-hydrolyzed under mild conditions (Raja 
et al. 1988), neutralized, size fractionated and weight-aver-
age mass was determined by light scattering (Baggenstoss 
and Weigel 2006). Biotinylated HA (b-HA; 108 kDa) was 
prepared by the method of Yu and Toole (1995), with slight 
modifications (Harris et al. 2007). Sodium 125I (100 mCi/mL; 
specific activity of >0.6 TBq/mg) in NaOH and Sepharose 
6 Fast Flow (Nickel NTA) resin were from GE/Amersham 
Biosciences (Piscataway, NJ). 125I-SA and 125I-HA were pre-
pared as described previously (Weigel 1980; Raja et al. 1984; 
McGary et al. 2003). Concentrator/desalting Centricon de-
vices were from Amicon (Bedford, MA). Endo-H (Strepto-
myces plicatus) was from Calbiochem (San Diego, CA). SA-
alkaline phosphatase conjugate, TFMS, trypsin and other 
salts and reagents were from Sigma-Aldrich (St. Louis, MO). 
PNGase-F (Flavobacterium meningosepticum), formic acid 
and sequence grade chymotrypsin, Asp-N, chymotrypsin/
trypsin and Asp-N/Glu-C were from Roche Applied Sci-
ence (San Francisco, CA). TFMS was from Acros Chemicals 
(Geel, Belgium). TBST contains 20 mM Tris–HCl, pH 7.0, 
150 mM NaCl and 0.1% (v/v) Tween-20. Hank’s balanced 
salt solution (HBSS) contains 5 mM KCl, 0.4 mM KH2PO4, 
pH 7.2, 0.8 mM MgSO4, 137 mM NaCl, 0.3 mM Na2HPO4, 
5.5 mM glucose, 1.26 mM CaCl2, 0.5 mM MgCl2 and 28 μM 
phenol red. 
Purification of 190-HARE ecto-domains
Recombinant s190-HARE, s190-HARE(N2280A) or s190-
HARE(ΔLink) was purified from conditioned cell culture 
medium by immobilized Ni-chelate affinity chromatography 
as described previously (Harris et al. 2007). Protein content, 
here and in general, was determined by A280 or by a dye-
binding method (Bradford 1976). Eluted fractions (pooled 
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and concentrated using a 30 MWCO concentrator) were 10–
20% pure, since some bovine serum proteins (e.g. α-2 macro-
globulin and H factor 1/complement) copurified. Impurities 
were removed after 5% SDS–PAGE (Laemmli 1970) by excis-
ing s190-HARE bands. After overnight electroelution (35 V, 
4°C) and subsequent concentration (Harris et al. 2007), the 
recovered s190-HARE was >98% pure, as assessed by SDS–
PAGE and silver staining. 
Trypsin digestion of s190-HARE prior to N-glycan 
determination
Partially purified s190-HARE was fractionated by SDS–
PAGE (Novex NuPAGE Tris-Acetate gel system; Invit-
rogen) and the gel stained by colloidal Coomassie. The 
s190-HARE band, identified by parallel western blotting 
(Burnette 1981), was excised and reduced in-gel in 600 mM 
Tris–HCl, pH 8.4, containing 2 mg/mL dithiothreitol (37°C 
for 45 min) and then carboxymethylated by addition of 
12 mg/mL iodoacetic acid (22°C for 1 h). Carboxymethyl-
ation was terminated by dialysis against 50 mM NH4HCO3, 
pH 8.5, at 4°C for 48 h, followed by lyophilization. Alkyl-
ated s190-HARE was incubated with trypsin (50:1 ratio, 
w/w) in 50 mM (NH4)HCO3, pH 8.4, for 16 h at 37°C. The 
digestion was terminated by heating at 100°C for 3 min, 
followed by C18 Sep-Pak chromatography (Waters Corp., 
Milford, MA, USA). Bound peptides were eluted with ei-
ther 20% (v/v) or 40% (v/v) propanol in 5% aqueous acetic 
acid, pooled and lyophilized. 
Preparation of N-glycans
PNGase-F (3 Roche units) digestion of tryptic peptides pre-
pared above or from the whole s190 was carried out in 
50 mM ammonium bicarbonate, pH 8.5, for 16 h at 37°C. Re-
leased N-glycans were separated from peptides using Sep-
Pak C18 cartridges (Waters Corp.) and permethylated using a 
sodium hydroxide procedure (Dell et al. 1993). 
Digestion of s190-HARE for glycoproteomic studies
Gel-purified 190-HARE was reduced and alkylated as de-
scribed above and digested with trypsin, chymotrypsin, 
Asp-N, Asp-N/Glu-C, chymotrypsin/trypsin or chymotryp-
sin/trypsin/Asp-N as described previously (Dell et al. 1993, 
1994). For CNBr cleavage, an aliquot of tryptically digested 
s190-HARE was dried down and resuspended in 100 μL 
of a 1 mL solution of 8 CNBr crystals dissolved in 70% for-
mic acid. Samples were incubated at 22°C overnight and re-
actions then stopped by adding 4 volumes of water and 
lyophilization. 
MS for glycan determination
MALDI-TOF MS data were acquired on a Voyager-DE 
sSTR mass spectrometer (PerSeptive Biosystems, Fram-
ingham, MA) in the reflectron mode with delayed extrac-
tion. Permethylated samples were dissolved in 10 µL of 
80% (v/v) methanol in water, and 1 µL of dissolved sam-
ple was premixed with 1 µL of matrix (10 mg/mL 2,5-dihy-
droxybenzoic acid in 80% (v/v) aqueous methanol) before 
loading onto a metal plate. MALDI-TOF/TOF experiments 
were performed on a 4800 Proteomics Analyzer (Applied 
Biosystems, Framingham, MA) in reflectron positive-ion 
mode. Both 2,5-dihydroxybenzoic acid and α-cyano-4-
hydroxycinnamic acid matrices (10 mg/mL in 50% (v/v) 
acetonitrile in 0.1% (v/v) aqueous trifluoroacetic acid) 
were used in conjunction with setting the potential differ-
ence between the source acceleration voltage and the colli-
sion cell at 1 kV to obtain different degrees and patterns of 
fragmentation. 
MS for peptide mapping
Digests were analyzed by nano-LC-ESI-MS/MS using a re-
verse-phase nano-high-performance liquid chromatogra-
phy (HPLC) system (Dionex, Sunnyvale, CA) connected to 
a quadrupole TOF mass spectrometer (Q-STAR Pulsar I, 
MDS Sciex). Components were separated by using a binary 
nano-HPLC gradient generated by an Ultimate pump fit-
ted with a Famos autosampler and a Switchos microcolumn 
switching module (LC Packings, Amsterdam, The Nether-
lands). An analytical C18 nanocapillary (75 µm inside diam-
eter × 15 cm, PepMap) and a micro precolumn C18 cartridge 
were employed for on-line peptide separation. The digest 
was first loaded onto the precolumn and eluted with 0.1% 
formic acid (Sigma) in water for 4 min. The eluent was then 
transferred onto an analytical C18 nanocapillary HPLC col-
umn and eluted at a flow rate of 150 nL/min using the fol-
lowing gradient of solvent A [0.05%, v/v formic acid in a 
95:5, v/v water/acetonitrile mixture] and solvent B [0.04% 
formic acid in a 95:5, v/v acetonitrile/water mixture]: 99% A 
from 0 to 5 min, 99–90% A from 5 to 10 min, 90–60% A from 
10 to 70 min, 60–50% A from 70 to 71 min, 50–5% A from 
71 to 75 min, 5% A from 75 to 85 min, 5–95% A from 85 to 
86 min and 95% A from 86 to 90 min. Data acquisition was 
performed using Analyst QS software with an automatic in-
formation-dependent acquisition function. 
Glycosidase treatments
Cells were lysed in phosphate buffered saline (PBS) with 
0.5% NP-40 containing protease inhibitors, debris was re-
moved by centrifugation and membrane-bound HARE was 
collected by incubation for 2 h at 22°C with 20 μL of a 1:1 
suspension of mAb-30 (Zhou et al. 2000) coupled to CNBr-
activated Sepharose 4B (1 mg/mL resin). After centrifuga-
tion, the supernatant was removed and PBS (20 μL) and 0.5% 
SDS (5 μL) were added to the resin, which was incubated at 
22°C for 10 min to dissociate HARE. The sample was cen-
trifuged, the supernatant containing HARE was placed in a 
0.2 mL screw cap microfuge tube and NP-40 was added to 
a final concentration of 2%. PNGase-F or Endo-H (1.25 mU) 
was added and the sample incubated for 16 h at 37°C. For 
purified soluble HARE proteins, 0.5 μg of protein in 2% 
NP-40 in PBS was incubated with enzyme under the same 
conditions. 
Chemical deglycosylation
Five micrograms of s190-HARE was lyophilized in a 1.5 mL 
tube and placed on ice. TFMS (70 μL) was mixed with 7.5 μL 
anisole, cooled on ice and added to the sample. The tube 
was shaken gently (not vortexed) until the protein was dis-
solved and the mixture incubated for 3 h on ice with occa-
sional mixing. Pyridine was chilled to −20°C in an ethanol/
dry ice bath, and 2 μL of 0.2% bromophenol blue in ethanol 
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(as a pH indicator) was added to the protein mixture. The 
red TFMS protein solution was cooled to −20°C and cold 
pyridine added until the solution turned yellow. To prevent 
solidification, 10 μL of water was added. More pyridine was 
added slowly, to minimize exothermic heating, until the so-
lution was purple/blue. Deglycosylated HARE was then di-
alyzed in three changes of 500 mL PBS over 10 h and stored 
at −80°C. 
Preparation of s190-HARE(N2280A) and 
190-HARE(N2280A) constructs
To make a N2280A mutant, two primers (forward: 
5 ′ -CTATGGACCTAGACCCGCCAAGAGTGAAAT -
GTGGG-3′ and reverse: 5′-CCCACATTTCACTCTTGGC-
GGGTCTAGGTCCATAG-3′) (altered codon is underlined) 
were used in individual mutagenic reactions with the WT 
190-HARE cDNA (in pSecTag/FRT/V5/His) in an Eri-
comp thermocycler (18 cycles: 94°C, 20 s; 62°C, 20 s; 71°C, 
1 min/plasmid kb) using pfu Ultra HF. Plasmids were etha-
nol precipitated, resuspended in 17 μL H2O, 2 μL NEB4 buf-
fer and 2.5 U of DpnI to cut template plasmids while retain-
ing intact mutant plasmids. After overnight incubation at 
37°C, the digestion mixtures were heated to 95°C for 10 min 
and immediately transformed into E. cloni 10G super-com-
petent E. coli cells (Lucigen, Middleton, WI). Bacterial cells 
were screened by a mini-prep procedure, PCR and DNA 
sequencing to confirm the mutation. Plasmids with cor-
rect mutations, open reading frames and promoter regions 
were used to make stable cell lines. A cDNA construct en-
coding the secreted ecto-domain was then produced from 
a validated 190-HARE(N2280A) cDNA using the primer 
(5′-GTGACCTTGACCCACACTGGATCCGAAGGTA-
AGCCTATC-3′) to delete the transmembrane and cytoplas-
mic domains, while retaining C-terminal V5 and His6 epit-
opes (Harris et al. 2007). 
Creation of Flp-In 293 cell lines expressing soluble or mem-
brane-bound 190-HARE(N2280A)
Cell lines with a single identical chromosome insertion site 
were created using recombinase-mediated integration in 
human Flp-In 293 cells (embryonic kidney derived) as de-
scribed previously (Harris et al. 2004, 2007). Multiple clones 
were tested for HARE expression by SDS–PAGE (5% gels) 
and western analysis (Burnette 1981) with anti-V5 Ab. Each 
positive clone was then tested for correct insertion of the 
pSecTag(190HARE) cDNA into the unique chromosomal 
Flp-In recombination site, mediated by the Flp-In recombi-
nase encoded by pOG44, using the assays described earlier 
(Harris et al. 2004, 2007). 
HA endocytosis assays
WT 190-HARE, EV, 190-HARE(ΔLink) and 190-HARE-
(N2280A) cells were grown in 24-well plates to ~90% conflu-
ence, washed and incubated in serum-free medium at 37°C 
for 1 h. Cells were washed with 1 mL HBSS and incubated 
at 37°C for the indicated times in 0.4 mL of Dulbecco’s mod-
ified Eagle’s medium (DMEM) containing 0.05% bovine se-
rum albumin and 1.0 µg/mL 125I-HA with or without a 100-
fold excess of unlabeled HA to assess nonspecific or total 
uptake, respectively. Medium was aspirated and cells were 
washed three times with 1 mL HBSS, solubilized in 1 mL 
0.3 N NaOH, and radioactivity (using a gamma counter) and 
protein were determined. Multiple experiments were per-
formed with different combinations of control and N2280A 
cell lines. Since receptor expression often differs among cell 
lines, HARE content was quantified by western analysis us-
ing 10 μg of cell lysate (in triplicate) and enhanced chemilu-
minescence according to the manufacturer’s instructions us-
ing Classic Blue BX film. Digital images were captured using 
a FluoroChem 8000 imaging system (Alpha Innotech Cor-
poration, San Leandro, CA), and band densities were quan-
tified as integrated densitometry values (i.e. the sum of all 
pixel values minus background correction). Values for spe-
cific endocytosis (total minus nonspecific) are presented as 
CPM/μg cell lysate protein (normalized to the mean inte-
grated digital value of each mutant compared to WT, which 
was 100%). 
35S Pulse-chase metabolic labeling 
190-HARE and 315-HARE cells were grown in DMEM with 
8% FBS and 100 μg/mL hygromycin B in 6-well dishes for 
2 days. Confluent cells were then washed twice with PBS, in-
cubated in DMEM without Met/Cys for 45 min, washed and 
1.0 mL of 37°C DMEM with 200 mCi/mL 35S-Met/Cys (no 
unlabeled Met/Cys) was added to each well. After 10 min at 
37°C, the media were aspirated, and the cells were washed 
twice in PBS and then incubated in fresh DMEM with 8% 
FBS at 37°C. At the indicated chase times, 0.5 mL of 4°C 
DMEM with 1.5% NP-40 and protease inhibitors was added, 
lysates were centrifuged to clear debris and HARE was re-
moved by incubation overnight at 4°C with CNBr-activated 
Sepharose 4B coupled to three anti-HARE mAbs (30, 154 and 
159). The resin was washed, bound proteins released with 
SDS, separated by 5% SDS–PAGE, and the gel was dried on 
filter paper and subjected to autoradiography using BioMax 
MS film (Kodak) for 2–7 days at −80°C. 
In vitro assays for HA binding to HARE ecto-domains
ELISA-Like Assay. HA (142 kDa) and T-10 dextran (as a 
control) were mixed separately in PBS at 50 μg/mL and in-
cubated overnight in heparin-binding plates (BD Biosci-
ences, San Jose, CA, USA). After blocking with 0.2% (w/v) 
gelatin in 0.2% (v/v) Tween-20, 100 mM NaCl, 50 mM so-
dium acetate, pH 7.2, the wells were washed and incubated 
with 1.0 μg/mL purified soluble WT, N2280A or ΔLink 
190-HARE ecto-domains for 1.5 h at 37°C. The wells were 
washed with 100 mM NaCl, 50 mM sodium acetate, 0.2% 
(v/v) Tween-20, pH 7.2 three times, and bound HARE was 
detected with anti-V5 Ab and alkaline phosphatase-anti goat 
IgG and color development using p-nitrophenylphosphate 
was quantified at A405 over 30 min. 
Ligand Blot Assay. Cell pellets were resuspended in 0.5% 
NP-40 with protease inhibitors, and 20 mg of total protein 
was separated by 5% (w/v) SDS–PAGE. Gels were electro-
transferred to nitrocellulose and incubated with 125I-HA as 
described previously (Yannariello-Brown et al. 1996). Af-
ter washing, bound 125I-HA was detected by autoradiog-
raphy using Kodak BioMax MS film. The blots were then 
processed for western analysis to identify HARE as noted 
above. 
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HA-HARE Pull-Down Assay. SA-Agarose CL-4B (25 μL, 
50% slurry; Fluka, Sigma-Aldrich) was mixed by rotation 
with 100 nM b-HA in TBST for 1 h at 22°C in a 1.5 mL tube. 
The resin was washed three times by centrifugation in TBST 
and incubated for 1 h at 37°C in 1 mL of TBST with 1 μg of 
s190-HARE, s190-HARE(N2280A) or s190-HARE(ΔLink). 
The resin was then washed three times with TBST, resus-
pended in 20 μL of 4× Laemmli buffer (Laemmli 1970) and 
subjected to 5% SDS–PAGE and western blotting using anti-
V5 Ab. HARE was visualized as above, and the bands were 
digitized and compared to the total protein used to assess 
the fraction bound to HA. 
SPR Assay. Experiments were performed at 37°C on a Bi-
acore 3000 (Biacore AB [GE Healthcare] Uppsala, Sweden). 
b-HA was captured on research grade SA-coated sensor 
chips (Sensor Chip SA, Biacore Inc.) pretreated according to 
the manufacturer’s instructions. A solution of b-HA (1.0 μg/
mL) was injected at 30 μL/min in PBS, pH 7, containing 
0.005% Tween 20 until a saturating amount of HA was cap-
tured on the surface (600 RU). The control surface contained 
only pretreated SA without b-HA on the same sensor chip. 
The specific HA binding of purified s190-HARE WT (posi-
tive control), ΔLink (negative control) and N2280A variant 
ecto-domains were measured using the Biacore 3000 in-line 
reference subtraction feature. Two concentrations (12.5 and 
50 nM) of each analyte were used to evaluate the kinetics of 
association (kon) and dissociation (koff, assessed in the same 
buffer without ecto-domain) at a flow rate of 5 μL/min over 
both surfaces of the sensor chip. Regeneration of the chip by 
stripping the analyte from the HA was performed by wash-
ing all surfaces with 5 M urea containing 0.2% SDS. Associa-
tion and dissociation rate constants were calculated using 1:1 
Langmuir modeling by the Biaevaluation software v3.2. 
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